Stockreport

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 [Yahoo! Finance]

VYNE Therapeutics Inc.  (VYNE) 
PDF Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line data expected in 2H'24 BRIDGEWATER, N.J., Ju [Read more]